Skip to main content

Trulicity FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved September 18, 2014)
Brand name: Trulicity
Generic name: dulaglutide
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diabetes, Type 2, Cardiovascular Risk Reduction

Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.

Development Timeline for Trulicity

DateArticle
Sep  3, 2020Approval  FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes
Feb 21, 2020Approval  Trulicity (dulaglutide) Approved to Reduce Cardiovascular Events in Adults With and Without Established Cardiovascular Disease
Sep 18, 2014Approval  FDA Approves Trulicity (dulaglutide) for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.